EICHORCondition: Ovarian Cancer · Ovarian Cyst Benign · Borderline Ovarian Cancer · Sponsor: ZIWIG
OVAmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in France; in order to describe the evolution of salivary miRNA expression between the pre-operative and post-therapy visits according to the type of mass. In time, the clinical application will be to significantly reduce the time to diagnosis and improve the care pathway for ovarian adnexal mass. The study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or MRI) and requiring surgical management in routine care. The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS, CNGOF. In this study, the management and follow-up of patients : * Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits, * Are not modified in comparison with the usual follow-up, except for the performance of the Collection of saliva
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patient over 18 years of age, * A patient with an ovarian adnexal mass diagnosed by clinical examination and imaging and likely to be ovarian cancer, a borderline tumour or a benign cyst, * Patient with an indication for surgery * Patient has dated and signed the consent form, * Patient affiliated to the healthcare system, Exclusion Criteria: * Pregnant patient * Patient infected with human immunodeficiency virus (HIV), * Patient with significant difficulties in reading or writing the French language. * Patient with another diagnosed cancer * Patient with a history of cancer less than 5 years old
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| CHU de Caen | Caen, Calvados, France | — |
| CGFL | Dijon, Côte d'Or, France | — |
| Institut Bergonié | Bordeaux, Gironde, France | — |
| CHU Strasbourg | Strasbourg, Haut-Rhin, France | — |
| CHU Toulouse | Toulouse, Haute-Garonne, France | — |
| CHP St Grégoire | Saint-Grégoire, Ille Et Villaine, France | — |
| Hôpital BICETRE | Le Kremlin-Bicêtre, Val de Marne, France | — |
| Institut Gustave Roussy | Villejuif, Val de Marne, France | — |
| CHU Angers | Angers, France | — |
| CH Bastia | Bastia, France | — |
| CHU Lyon Sud / Hospices Civils de Lyon | Lyon, France | — |
| Centre Antoine Lacassagne | Nice, France | — |
+ 9 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05514028